IGHE and asthma: In fact, the approach of carrier‐bound B‐cell epitope‐containing peptides which is a second‐generation hypoallergenic approach characterized by a profound reduction in IgE‐mediated allergenic activity and a reduction in T‐cell–mediated side effects would seem particularly suitable for asthma treatment.139